Other groups have developed bsAb-based molecules that simultaneously target two tumour-associated antigens such as EGFR and insulin growth factor receptor (IGFR) (Lu et al, 2005) or carcinoembryonic antigen (CEA) and ErbB2 (Dorvillius et al, 2002). Here, IGF1R is linked to neoplasm.